NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free BEAM Stock Alerts $24.87 -0.37 (-1.47%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$24.60▼$25.4150-Day Range$21.22▼$29.3252-Week Range$16.95▼$49.50Volume1.77 million shsAverage Volume1.06 million shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/APrice Target$40.18 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Beam Therapeutics alerts: Email Address Beam Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside61.6% Upside$40.18 Price TargetShort InterestBearish16.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 5 Articles This WeekInsider TradingSelling Shares$3.16 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.68) to ($4.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.42 out of 5 starsMedical Sector725th out of 914 stocksBiological Products, Except Diagnostic Industry119th out of 153 stocks 3.2 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Beam Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.80% of the outstanding shares of Beam Therapeutics have been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently decreased by 5.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BEAM. Previous Next 1.5 News and Social Media Coverage News SentimentBeam Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Beam Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,163,729.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($4.68) to ($4.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -13.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -13.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Beam Therapeutics Stock (NASDAQ:BEAM)Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More BEAM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BEAM Stock News HeadlinesJune 14 at 3:00 AM | globenewswire.comBeam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell DiseaseJune 11, 2024 | americanbankingnews.comAnalysts Set Beam Therapeutics Inc. (NASDAQ:BEAM) PT at $40.18May 30, 2024 | globenewswire.comBeam Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 29, 2024 | msn.comDebunking Common Myths About Radiation TherapyMay 14, 2024 | globenewswire.comBeam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressMay 13, 2024 | msn.comWirral patient first to access laser beam surgery to prevent epileptic seizuresMay 12, 2024 | msn.comLancashire NHS patients to access world-leading laser beam surgery to prevent epileptic seizuresMay 11, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)May 9, 2024 | finance.yahoo.comBeam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 9, 2024 | investorplace.comBiotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing MedicineMay 8, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Travere Therapeutics (TVTX) and Oscar Health (OSCR)May 8, 2024 | globenewswire.comBeam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceMay 7, 2024 | finance.yahoo.comBeam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed OverviewMay 7, 2024 | investorplace.comBEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | globenewswire.comBeam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsMay 6, 2024 | msn.comEpilepsy patients to be offered ‘game-changing’ laser therapy in NHS rolloutMay 2, 2024 | theglobeandmail.comThe best and worst recent ETF performers and the stock trends they revealMay 2, 2024 | finance.yahoo.comIBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, USMay 1, 2024 | yahoo.comOU researchers develop new technology to improve bridges and roadsMay 1, 2024 | msn.comThe Days of Our Lives Superstar Casting That Would Blow Things *All* the Way Up - Not Just for Jada But Salem!May 1, 2024 | finance.yahoo.comBest Theratronics workers go on strike after company's 0% offerMay 1, 2024 | msn.comBest Puzzle Games On Game PassApril 30, 2024 | dailymail.co.ukWarner Bros. lands seven-figure rights deal for Avengelyne starring Margot Robbie with Olivia Wilde set to direct the comic book adaptationApril 30, 2024 | yahoo.comWe Tested (and Rated!) All the Dining Tables at Pottery Barn — Here Are the Best to Suit Your Style and SpaceSee More Headlines Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/15/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees436Year Founded2017Price Target and Rating Average Stock Price Target$40.18 High Stock Price Target$57.00 Low Stock Price Target$20.00 Potential Upside/Downside+61.6%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,530,000.00 Net Margins-37.33% Pretax Margin-36.95% Return on Equity-15.46% Return on Assets-9.86% Debt Debt-to-Equity RatioN/A Current Ratio5.99 Quick Ratio5.99 Sales & Book Value Annual Sales$377.71 million Price / Sales5.42 Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book2.07Miscellaneous Outstanding Shares82,310,000Free Float78,854,000Market Cap$2.05 billion OptionableOptionable Beta1.89 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. John M. Evans M.B.A. (Age 46)CEO & Director Comp: $1.11MDr. Giuseppe Ciaramella Ph.D. (Age 55)President Comp: $933.2kMs. Terry-Ann Burrell M.B.A. (Age 47)CFO & Treasurer Comp: $711.15kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D.Co-FounderDr. Alexis Komor Ph.D.Co-FounderDr. Manmohan Singh Ph.D.Chief Technology OfficerDr. Gopi Shanker Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsIntellia TherapeuticsNASDAQ:NTLAReplimune GroupNASDAQ:REPLEditas MedicineNASDAQ:EDITSangamo TherapeuticsNASDAQ:SGMOAlloVirNASDAQ:ALVRView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 406,000 shares on 5/24/2024Ownership: 5.481%Virtu Financial LLCBought 26,486 shares on 5/20/2024Ownership: 0.032%Walleye Trading LLCSold 27,400 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 2,066 shares on 5/16/2024Ownership: 0.085%Bayesian Capital Management LPBought 8,803 shares on 5/16/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions BEAM Stock Analysis - Frequently Asked Questions Should I buy or sell Beam Therapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares. View BEAM analyst ratings or view top-rated stocks. What is Beam Therapeutics' stock price target for 2024? 13 brokerages have issued 1 year price objectives for Beam Therapeutics' stock. Their BEAM share price targets range from $20.00 to $57.00. On average, they expect the company's share price to reach $40.18 in the next twelve months. This suggests a possible upside of 61.6% from the stock's current price. View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts. How have BEAM shares performed in 2024? Beam Therapeutics' stock was trading at $27.22 on January 1st, 2024. Since then, BEAM stock has decreased by 8.6% and is now trading at $24.87. View the best growth stocks for 2024 here. Are investors shorting Beam Therapeutics? Beam Therapeutics saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 13,830,000 shares, a decrease of 5.1% from the May 15th total of 14,580,000 shares. Based on an average trading volume of 1,260,000 shares, the short-interest ratio is currently 11.0 days. View Beam Therapeutics' Short Interest. When is Beam Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our BEAM earnings forecast. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.21. The company had revenue of $7.40 million for the quarter, compared to the consensus estimate of $17.09 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 15.46% and a negative net margin of 37.33%. The firm's quarterly revenue was down 69.4% on a year-over-year basis. During the same quarter last year, the business posted ($1.33) earnings per share. What ETFs hold Beam Therapeutics' stock? ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), ARK Innovation ETF (ARKK), iShares Genomics Immunology and Healthcare ETF (IDNA), Horizon Kinetics Medical ETF (MEDX) and WisdomTree BioRevolution Fund (WDNA). What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Beam Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.21%), Farallon Capital Management LLC (5.48%), Sumitomo Mitsui Trust Holdings Inc. (2.89%), Nikko Asset Management Americas Inc. (2.87%), Darwin Global Management Ltd. (2.58%) and Redmile Group LLC (2.28%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..Read More This page (NASDAQ:BEAM) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.